Sangamo BioSciences | SGMO - Equity Capital And Reserves


Sangamo BioSciences reported $19.6M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.





Equity Capital And Reserves Change Date
Alaunos Therapeutics USD 2.15M 650K Dec/2025
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Alterity Therapeutics Limited AUD 36.21M 18.58M Dec/2025
Amgen USD 9.19B 532M Mar/2026
Bayer EUR 25.95B 3.75B Dec/2025
BioCryst Pharmaceuticals USD -119.15M 268.74M Dec/2025
Biogen USD 18.65B 394.9M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Cipla INR 329.19B 16.3B Sep/2025
Clal Biotechnology ILS 121.41M 4.62M Dec/2023
Compugen USD 102.73M 58.9M Dec/2025
CSL USD 18.66B 2.75B Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Grifols EUR 6.21B 133.12M Dec/2025
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
J&J USD 81.19B 358M Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Merck USD 45.88B 6.73B Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Omeros USD -228.68M 15.13M Jun/2025
Pfizer USD 90.1B 3.63B Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 72.81B 1.1B Mar/2026
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
Tectonic Therapeutic USD 251.33M 16.2M Dec/2025
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026